BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 32595989)

  • 1. Effect of Timing of Gonadotropin-Releasing Hormone Agonist Administration for Ovarian Protection in Patients with Breast Cancer.
    Shin JJ; Choi YM; Jun JK; Lee KH; Kim TY; Han W; Im SA
    J Breast Cancer; 2020 Jun; 23(3):268-278. PubMed ID: 32595989
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prediction of ovarian function recovery in young breast cancer patients after protection with gonadotropin-releasing hormone agonist during chemotherapy.
    Lee DY; Park YH; Lee JE; Choi D
    Breast Cancer Res Treat; 2018 Oct; 171(3):649-656. PubMed ID: 29943121
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ovarian reserve in premenopausal women with breast cancer.
    Zong X; Yu Y; Chen W; Zong W; Yang H; Chen X
    Breast; 2022 Aug; 64():143-150. PubMed ID: 35691250
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gonadotropin-releasing hormone agonist protects ovarian function in young patients with ovarian malignancy undergoing platinum-based chemotherapy: A prospective study.
    Xie Y; Duan H; Wang D; Li H; Jia J; Zhang J; Li L
    Front Oncol; 2022; 12():986208. PubMed ID: 36338740
    [TBL] [Abstract][Full Text] [Related]  

  • 5. GnRHa for Ovarian Protection and the Association between AMH and Ovarian Function during Adjuvant Chemotherapy for Breast Cancer.
    Zhong Y; Lin Y; Cheng X; Huang X; Zhou Y; Mao F; Wang Y; Guan J; Shen S; Xu Y; Peng L; Li Y; Cao X; Sun Q
    J Cancer; 2019; 10(18):4278-4285. PubMed ID: 31413747
    [No Abstract]   [Full Text] [Related]  

  • 6. Prediction of Successful Ovarian Protection Using Gonadotropin-Releasing Hormone Agonists During Chemotherapy in Young Estrogen Receptor-Negative Breast Cancer Patients.
    Lee DY; Kim JY; Yu J; Kim SW
    Front Oncol; 2020; 10():863. PubMed ID: 32656076
    [No Abstract]   [Full Text] [Related]  

  • 7. Longitudinal study of AMH variations in 122 Adolescents and Young Adults (AYA) and non-AYA lymphoma patients to evaluate the chemo-induced ovarian toxicity to further personalise fertility preservation counselling.
    Decanter C; Delepine J; Behal H; Manier S; Bruno B; Barbatti M; Robin C; Labreuche J; Morschhauser F; Pigny P
    Hum Reprod; 2021 Sep; 36(10):2743-2752. PubMed ID: 34417822
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Anti-Müllerian hormone as a new marker of the ovarian reserve function preservation by goserelin during (neo)adjuvant chemotherapy for young breast cancer patients].
    Wang SY; Wang S
    Beijing Da Xue Xue Bao Yi Xue Ban; 2019 Jun; 51(3):536-541. PubMed ID: 31209428
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gonadotropin-Releasing Hormone Agonist Cotreatment During Chemotherapy May Increase Pregnancy Rate in Survivors.
    Blumenfeld Z; Zur H; Dann EJ
    Oncologist; 2015 Nov; 20(11):1283-9. PubMed ID: 26463871
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of Gonadotropin-Releasing Hormone Analogs on Ovarian Function Against Chemotherapy-Induced Gonadotoxic Effects in Premenopausal Women With Breast Cancer in China: A Randomized Clinical Trial.
    Zong X; Yu Y; Yang H; Chen W; Ding X; Liu S; Li X; Chen X; Jiang C; Xia X; Huang R; Zhu M; Hu J; Liang C
    JAMA Oncol; 2022 Feb; 8(2):252-258. PubMed ID: 34967844
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ProFertil study protocol for the investigation of gonadotropin-releasing hormone agonists (GnRHa) during chemotherapy aiming at fertility protection of young women and teenagers with cancer in Sweden-a phase III randomised double-blinded placebo-controlled study.
    Rodriguez-Wallberg KA; Nilsson HP; Bergh J; Malmros J; Ljungman P; Foukakis T; Stragliotto CL; Friman EI; Linderholm B; Valachis A; Andersson A; Harrysson S; Vennström L; Frisk P; Mörse H; Eloranta S
    BMJ Open; 2023 Dec; 13(12):e078023. PubMed ID: 38070906
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of depot GnRH agonist on AMH levels in healthy reproductive-aged women.
    Su HI; Maas K; Sluss PM; Chang RJ; Hall JE; Joffe H
    J Clin Endocrinol Metab; 2013 Dec; 98(12):E1961-6. PubMed ID: 24081742
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Triggering final oocyte maturation with gonadotropin-releasing hormone agonist (GnRHa) versus human chorionic gonadotropin (hCG) in breast cancer patients undergoing fertility preservation: an extended experience.
    Reddy J; Turan V; Bedoschi G; Moy F; Oktay K
    J Assist Reprod Genet; 2014 Jul; 31(7):927-32. PubMed ID: 24854484
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factors affecting the distribution of serum anti-müllerian hormone levels among infertile Asian women: a multi-nation, multi-centre, and multi-ethnicity prospective cohort study.
    Tzeng CR; Huang Z; Asada Y; Zhang C; Ho MT; Li RHW; Kim JH; Govindarajan M; Vuyavanich T; Sini I; Wong PS; Singh S; Lin WY; Ho NT
    Hum Reprod; 2023 Jul; 38(7):1368-1378. PubMed ID: 37105234
    [TBL] [Abstract][Full Text] [Related]  

  • 15. No Evidence for the Benefit of Gonadotropin-Releasing Hormone Agonist in Preserving Ovarian Function and Fertility in Lymphoma Survivors Treated With Chemotherapy: Final Long-Term Report of a Prospective Randomized Trial.
    Demeestere I; Brice P; Peccatori FA; Kentos A; Dupuis J; Zachee P; Casasnovas O; Van Den Neste E; Dechene J; De Maertelaer V; Bron D; Englert Y
    J Clin Oncol; 2016 Aug; 34(22):2568-74. PubMed ID: 27217453
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prechemotherapy antimullerian hormone, age, and body size predict timing of return of ovarian function in young breast cancer patients.
    Su HC; Haunschild C; Chung K; Komrokian S; Boles S; Sammel MD; DeMichele A
    Cancer; 2014 Dec; 120(23):3691-8. PubMed ID: 25081546
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of goserelin and leuprorelin for ovarian protection during chemotherapy in young patients with breast cancer.
    Kim SE; Kim WJ; Choi D; Lee DY
    Breast Cancer Res Treat; 2023 Apr; 198(2):231-237. PubMed ID: 36781519
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Feasibility and efficacy of gonadotropin-releasing hormone agonists for the prevention of chemotherapy-induced ovarian insufficiency in patients with malignant ovarian germ cell tumours (KGOG 3048R).
    Choi MC; Chung YS; Lee JW; Kwon BS; Park BK; Kim SI; Shim SH; Lee KB; Seong SJ; Lee SJ; Lee SH; Yoo HJ; Song T; Kim MK; Baek MH; Kang S; Kim YM
    Eur J Cancer; 2020 Jul; 133():56-65. PubMed ID: 32442924
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gonadotropin-Releasing Hormone Agonists for Ovarian Function Preservation in Premenopausal Women Undergoing Chemotherapy for Early-Stage Breast Cancer: A Systematic Review and Meta-analysis.
    Munhoz RR; Pereira AA; Sasse AD; Hoff PM; Traina TA; Hudis CA; Marques RJ
    JAMA Oncol; 2016 Jan; 2(1):65-73. PubMed ID: 26426573
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gonadotrophin-releasing hormone agonists for fertility preservation: unraveling the enigma?
    Hasky N; Uri-Belapolsky S; Goldberg K; Miller I; Grossman H; Stemmer SM; Ben-Aharon I; Shalgi R
    Hum Reprod; 2015 May; 30(5):1089-101. PubMed ID: 25796551
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.